© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
August 23, 2022
“There has never been a clinical trial for these patients. It is unclear whether these patients should be treated with medication, surgery, or another approach. This represents an unmet medical need,” said Raquibul Hannan, MD, PhD.
August 01, 2022
The focus of the analysis was to determine the HRQOL of patients who were enrolled on the phase 3 KEYNOTE-426 trial.
July 29, 2022
Patients in the CheckMate-914 trial had received radical or partial nephrectomy and were at moderate or high risk of relapse.
July 22, 2022
“Survival differences can be due in part to genetic differences, but also a lot of socioeconomic issues as well,” says Ridwan Alam, MD.
July 21, 2022
Ridwan Alam, MD, discusses research exploring nonclinical factors affecting overall survival in patients with renal cell carcinoma.
July 11, 2022
Exelixis plans to discuss the top level results of the phase 3 COSMIC-313 trial with the FDA regarding a potential application submission for the triplet in this setting.
July 05, 2022
“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.
July 01, 2022
Understanding the mechanisms of treatment resistance is among the areas of unmet need, says James Brugarolas, MD, PhD.
June 30, 2022
Tivozanib (Fotivda) is approved by the FDA for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.
June 27, 2022
“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.